8YKI

FGFR-1 in complex with ligand tasurgratinib

これはPDB形式変換不可エントリーです。

8YKI の概要

• エントリーDOI: 10.2210/pdb8yki/pdb
• 分子名称: Fibroblast growth factor receptor 1, Tasurgratinib, CHLORIDE ION, ... (4 entities in total)
• 機能のキーワード: fgf receptor kinase, proteros biostructures gmbh, transferase
• 由来する生物種: Homo sapiens (human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 73479.18

構造登録者

Ikemori-Kawada, M.,Watanabe Miyano, S. (登録日: 2024-03-05, 公開日: 2024-06-12)

主引用文献

Kawano, S.,Kawada, M.I.,Fukushima, S.,Arai, Y.,Shibata, T.,Miyano, S.W.
Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion.
Anticancer Res., 44:2393-2406, 2024

PubMed Abstract: Cholangiocarcinoma (CCA) is an aggressive tumor with limited treatment options especially in 2nd line or later treatments. Targeting fibroblast growth factor receptor (FGFR) 2 has recently emerged as a promising treatment option for patients with CCA harboring FGFR2-fusion. This study investigated the antitumor activities of tasurgratinib as an orally available FGFR1-3 inhibitor, in preclinical FGFR2-driven CCA models.

PubMed: 38821585
DOI: 10.21873/anticanres.17046

実験手法

X-RAY DIFFRACTION (2.79 Å)